NDAORALTABLETPriority Review
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REVUFORJ (revumenib) is an oral tablet approved by the FDA on November 15, 2024, representing a new chemical entity from Syndax Pharmaceuticals currently in growth lifecycle stage. Mechanism of action and specific indications are not yet publicly detailed in available data.
Growth16.2 years to LOE
Recent approval positions this as a growth-stage asset with expanding commercial infrastructure needs; team scaling likely underway across sales, marketing, and medical affairs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
Revumenib in Patients With Myelofibrosis
Started Dec 2026
32 enrolled
MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Started Nov 2026
20 enrolled
BlinatumomabRevumenibLymphoblastic Leukemia+1 more
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Started Nov 2025
468 enrolled
Acute Myeloid Leukemias
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Started Mar 2025
415 enrolled
Acute Myeloid Leukemia, Adult
Revumenib in Combination With 7+3 + Midostaurin in AML
Started Dec 2024
22 enrolled
Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more
Worked on REVUFORJ at Syndax Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.